Comparative Pharmacology
Head-to-head clinical analysis: M V I PEDIATRIC versus RUVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: M V I PEDIATRIC versus RUVITE.
M.V.I. PEDIATRIC vs RUVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Multivitamin preparation providing essential vitamins (A, C, D, E, K, B1, B2, B3, B5, B6, B7, B9, B12) as cofactors for enzymatic reactions, antioxidant functions, and maintenance of normal metabolic processes.
RUVITE (ruxolitinib) is a Janus kinase (JAK) inhibitor, specifically inhibiting JAK1 and JAK2, which mediates signaling of cytokines and growth factors involved in hematopoiesis and immune function.
Intravenous infusion: 5 mL (1 vial) added to appropriate IV fluid, administered over 30 minutes daily.
100 mg orally once daily with or without food.
None Documented
None Documented
Variable; vitamin A: 9-25 days (stored in liver), vitamin D: 2-3 weeks (fat-soluble), vitamin C: 10-20 hours (renal function dependent), B-complex: 1-10 hours. Clinical context: accumulation risk in renal impairment.
The terminal elimination half-life is approximately 2-4 hours in patients with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), the half-life may be prolonged to 8-12 hours, necessitating dose adjustment.
Renal: 60-80% (free vitamins), Biliary/fecal: 10-20% (unabsorbed and metabolites).
Renal excretion of unchanged drug accounts for approximately 30-50% of the administered dose; biliary/fecal elimination accounts for the remainder, with 20-30% recovered in feces as metabolites and parent drug. Total clearance is about 100-150 mL/min.
Category C
Category C
Multivitamin
Multivitamin